PO.MCB07.01 · 分子与细胞生物学

Molecular features of patient-derived triple-negative breast cancer models based on super-enhancer-associated transcriptional regulators and biomarkers

编号 4770 展板 20 时间 4/21 09:00–12:00 区域 Section 24 主讲 Kuniko Horie, MD;PhD
分会场 Oncogenic Transcription Factors and Cancer Programs
该海报暂无可访问的完整资料 AACR 官方页面 ↗

作者与单位

Kuniko Horie1, Kazuhiro Ikeda1, Satoshi Inoue2

1Saitama Medical University, Saitama, Japan,2Professor, Dept. of Anti-Aging Med., TMIG - Tokyo Metropolitan Institute of Gerontology, Tokyo, Japan

摘要 Abstract

Super-enhancers (SEs) have been defined as particular genomic regions with clusters of consecutive enhancers, which provide cell- or stage-specific context. SEs are often determined by high-level enrichment for genomic binding of transcriptional coactivators and active chromatin marks such as histone H3 with acetylated K27. In this study, we aim to characterize similarity and specificity of SE-associated gene profiles of patient-derived models of triple-negative breast cancer (TNBC) obtained from distinct advanced cases. We identified SE-associated genes for these models based on the integrated study of RNA-sequencing and chromatin immunoprecipitation (ChIP) sequencing for H3K27ac binding. Since these patient-derived cancer models were generated through a spheroid culture technique, stemness markers such as CD44 and MYC were identified as predominant SE-associated genes in the majority of cases. We further identified MYBL1 as a critical SE-associated transcription factor among basal-like cancer cases. Silencing of MYBL1 in TNBC patient-derived and cell line models showed that this transcription factor contributes to cell proliferation and the regulation of mitosis-associated gene expression. Immunohistochemical study for MYBL1 in our TNBC cohort showed that MYBL1 immunoreactivity is a potential poor prognostic factor for TNBC patients. The present findings suggest that the characterization of SE-associated transcriptional regulators and biomarkers will facilitate the understanding of molecular features of TNBC subtypes and the development of alternative potential therapeutic targets for the advanced disease.
利益披露 Disclosure
K. Horie, None.. K. Ikeda, None.

在会议检索中打开